- Home
- SCNI
as 07-26-2024 4:00pm EST
BiondVax Pharmaceuticals Ltd is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses. It has executed eight clinical trials in seven countries, around 12,400 participants in the Phase 3 trial of its vaccine candidate and has built a GMP biologics manufacturing facility for biopharmaceutical products. The company is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with an innovative nanosized antibody (NanoAb) pipeline.
| Founded: | 2003 | Country: | Israel |
| Employees: | N/A | City: | JERUSALEM |
| Market Cap: | 1.7M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 1.6M |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -13.12 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.23 - $14.20 | Next Earning Date: | 08-09-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Scinai Immunotherapeutics Ltd. News
SCNI Breaking Stock News: Dive into SCNI Ticker-Specific Updates for Smart Investing
PR Newswire
4 days ago
Scinai Immunotherapeutics Announces Positive Regulatory Feedback from the PEI on the path for Phase 1/2a in Plaque Psoriasis with its anti-IL-17 nanoAb
PR Newswire
12 days ago
Scinai Immunotherapeutics Announces promising results in an in-vivo proof-of-concept psoriatic human skin model
PR Newswire
19 days ago
Scinai Immunotherapeutics Announces Receipt of an Updated Letter of Intent from the European Investment Bank Providing Specific Terms for Conversion of its Loan to Equity
PR Newswire
23 days ago
Scinai Immunotherapeutics Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements
PR Newswire
25 days ago
Scinai Publishes Q1 2024 Financial Results and Provides Business Update
PR Newswire
a month ago
Scinai Immunotherapeutics Announces Receipt of a Letter of Intent from the European Investment Bank Providing Specific Terms for Conversion of its Loan to Equity.
CNW Group
2 months ago
Start Proud Opens the Market
Associated Press Finance
2 months ago
Will recreational pot go on sale soon in Ohio? Medical marijuana stores can now apply to sell it
Compare SCNI vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SCNI Scinai Immunotherapeutics Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.